AbbVie lowers 2023 adjusted EPS guidance by $0.08 on $150M Q1 IPR&D expense

AbbVie Inc.

2023-Q1 EPS reported $0.13 revenue$12,225,000,000

Q1 2023 acquired IPR&D and milestones expense of $150M pre-tax reduces GAAP and adjusted EPS by $0.08.
Q1 2023 adjusted diluted EPS guidance lowered to $2.31-$2.41 from $2.39-$2.49.
Full-year 2023 adjusted diluted EPS guidance lowered to $10.62-$11.02 from $10.70-$11.10.
Company does not forecast future IPR&D and milestones expense; guidance excludes any beyond Q1.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.